Updated from 10:30 a.m. EDTRoche's $89-a-share offer for Genentech (DNA) is notable not just for the fact that it could mark the end of an era for the best biotech in the history of the industry, but for the repercussions it could potentially have on the rest of the sector.
Roche Bid Could Alter Pharma's DNA
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.